查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553538

雌激素受体阳性乳癌治疗市场规模、份额、趋势分析报告：按治疗、最终用途、地区和细分市场预测，2024-2030 年

Estrogen Receptor Positive Breast Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

雌激素受体阳性乳癌治疗市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球雌激素受体阳性乳癌治疗市场预计将达到337亿美元，2024年至2030年复合年增长率为7.89%。

这个市场包括专门针对和管理这种乳癌亚型而设计的各种治疗方案。

药物开发创新正在对 ER+ 乳癌治疗市场产生重大影响。新的治疗方法包括新型Aromatase抑制剂、选择性雌激素受体降解剂（SERD）和标靶治疗。例如，2023年1月，FDA批准了Aucerdue，一种口服处方药，用于治疗ESR1突变的转移性雌激素受体阳性、HER2阴性乳癌，强调了向个人化治疗策略的转变。

製药公司、生技公司和研究机构之间的策略联盟与合作对 ER+ 乳癌治疗市场产生重大影响。例如，美纳里尼集团于 2024 年 6 月与In Silico Medicine 签署了开发新型 KAT6A 抑制剂的授权协议，凸显了双方共同努力推进癌症治疗趋势的趋势。这些合作关係通常会加速药物开发并提供更全面的治疗选择，从而加强整体 ER+ 乳癌治疗格局并有助于市场扩张。

雌激素受体阳性乳癌治疗市场报告亮点

  • 从治疗方式来看，荷尔蒙疗法在2023年占据市场主导地位。这是由于其在改善患者预后方面的功效、与化疗等其他治疗方法相比有利的副作用、作为维持治疗的长期适用性、指南的大力支持、患者的偏好趋势、有利于成本效益治疗的经济考虑、进展生物标记测试促进个人化医疗方法，并持续研究导致该类别的新治疗选择。
  • 从最终用途来看，医院占据市场主导地位，2023 年销售份额最大，为 62.48%。这是由于多学科团队有能力提供全面的护理、获得包括临床试验在内的先进治疗、有利于具有复杂需求的老年患者的人口因素以及有关保险范围和成本效率考虑的经济学，包括其在研发中的关键作用。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章雌激素受体阳性乳癌治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 雌激素受体阳性乳癌治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第 4 章 雌激素受体阳性乳癌治疗市场：依治疗分类的估计与趋势分析

  • 全球雌激素受体阳性乳癌治疗市场：治疗仪表板
  • 全球雌激素受体阳性乳癌治疗市场：治疗变异分析
  • 全球雌激素受体阳性乳癌治疗市场：按治疗分類的收益
  • 化疗
  • 标靶治疗
  • 荷尔蒙疗法
  • 放射治疗
  • 其他的

第五章雌激素受体阳性乳癌治疗市场：最终用途的估计和趋势分析

  • 全球雌激素受体阳性乳癌治疗市场：最终用途仪表板
  • 全球雌激素受体阳性乳癌治疗市场：最终用途变化分析
  • 全球雌激素受体阳性乳癌治疗市场：按最终用途分類的收益
  • 医院
  • 专科诊所
  • 其他的

第六章雌激素受体阳性乳癌治疗市场：按治疗和最终用途分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2023年主要企业市场占有率分析
    • Radius Health, Inc.
    • Sanofi
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Lilly
    • EQRx, Inc.
    • Gilead Sciences, Inc.
    • Sermonix Pharmaceuticals
    • Tyme Limited
    • Genentech, Inc.
Product Code: GVR-4-68040-422-8

Estrogen Receptor Positive Breast Cancer Treatment Market Growth & Trends:

The global estrogen receptor positive breast cancer treatment market is anticipated to reach USD 33.7 billion by 2030 and is projected to grow at a CAGR of 7.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market includes a variety of therapeutic options specifically designed to target and manage this subtype of breast cancer.

Innovations in drug development are significantly impacting the ER+ breast cancer treatment market. New therapies include novel aromatase inhibitors, selective estrogen receptor degraders (SERDs), and targeted treatments. For instance, in January 2023, the FDA authorized Orserdu, an oral prescription for metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation, underscoring a shift towards personalized treatment strategies.

Strategic collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions significantly impact the market for ER+ breast cancer treatment. For instance, in June 2024, Menarini Group's licensing agreement with Insilico Medicine to develop a new KAT6A inhibitor underscores the trend toward collaborative efforts to advance oncology treatments. These partnerships often lead to accelerated drug development and more comprehensive treatment options, enhancing the overall treatment landscape for ER+ breast cancer and contributing to market expansion.

Estrogen Receptor Positive Breast Cancer Treatment Market Report Highlights:

  • Based on treatment, hormonal therapy dominated the market in 2023 due to its efficacy in improving patient outcomes, favorable side effect profiles compared with other modalities such as chemotherapy, long-term applicability as maintenance therapy, strong guideline support, patient preference trends towards less invasive options, economic considerations favoring cost-effective treatments, advancements in biomarker testing facilitating personalized medicine approaches, and continuous research leading to new therapeutic options within this category.
  • Based on end use, hospitals dominated the market with the largest revenue share of 62.48% in 2023 due to their ability to provide comprehensive care through multidisciplinary teams, access to advanced treatments including clinical trials, demographic factors favoring older patients with complex needs, economic considerations regarding insurance coverage and cost efficiency, and their pivotal role in R&D efforts to improve patient outcomes.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Estrogen Receptor Positive Breast Cancer Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High incidence and prevalence of ER+ breast cancer
      • 3.2.1.2. Availability of endocrine therapies targeting ER
      • 3.2.1.3. Increasing adoption of targeted therapies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited treatment options for resistant cases
      • 3.2.2.2. High costs associated with advanced therapies
  • 3.3. Estrogen Receptor Positive Breast Cancer Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Dashboard
  • 4.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Movement Analysis
  • 4.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market by Treatment, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Hormonal Therapy
    • 4.6.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Estimates & Trend Analysis

  • 5.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Dashboard
  • 5.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Movement Analysis
  • 5.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Estrogen Receptor Positive Breast Cancer Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. Radius Health, Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Sanofi
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. F. Hoffmann-La Roche Ltd
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. AstraZeneca
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Lilly
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. EQRx, Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Gilead Sciences, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Sermonix Pharmaceuticals
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Tyme Limited
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Genentech, Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 U.S. Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 Canada Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Mexico Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 France Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33 China Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 China Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Japan Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 India Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 India Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Australia Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Latin America Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 47 Latin America Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Brazil Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Argentina Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 MEA Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 MEA Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 55 South Africa Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 South Africa Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 UAE Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Estrogen receptor positive breast cancer treatment market: market outlook
  • Fig. 7 Estrogen receptor positive breast cancer treatment competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Estrogen receptor positive breast cancer treatment market driver impact
  • Fig. 11 Estrogen receptor positive breast cancer treatment market restraint impact
  • Fig. 12 Estrogen receptor positive breast cancer treatment market: Treatment movement analysis
  • Fig. 13 Estrogen receptor positive breast cancer treatment market: Treatment outlook and key takeaways
  • Fig. 14 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Hormonal therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Radiation therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Estrogen receptor positive breast cancer treatment market: End Use movement analysis
  • Fig. 20 Estrogen receptor positive breast cancer treatment market: End Use outlook and key takeaways
  • Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Specialty Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global Estrogen receptor positive breast cancer treatment market: Regional movement analysis
  • Fig. 25 Global Estrogen receptor positive breast cancer treatment market: Regional outlook and key takeaways
  • Fig. 26 Global Estrogen receptor positive breast cancer treatment market share and leading players
  • Fig. 27 North America, by country
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. key country dynamics
  • Fig. 30 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada key country dynamics
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico key country dynamics
  • Fig. 34 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK key country dynamics
  • Fig. 37 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Germany key country dynamics
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France key country dynamics
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy key country dynamics
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Spain key country dynamics
  • Fig. 45 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark key country dynamics
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden key country dynamics
  • Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Norway key country dynamics
  • Fig. 51 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 China key country dynamics
  • Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Japan key country dynamics
  • Fig. 56 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 India key country dynamics
  • Fig. 58 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand key country dynamics
  • Fig. 60 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea key country dynamics
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Australia key country dynamics
  • Fig. 64 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil key country dynamics
  • Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina key country dynamics
  • Fig. 69 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa key country dynamics
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia key country dynamics
  • Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 UAE key country dynamics
  • Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait key country dynamics
  • Fig. 78 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Market share of key market players- Estrogen receptor positive breast cancer treatment market